KAT2B and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting the PCAF alone or in combination with DNA-damaging drugs shows cytotoxic effects and should be considered as a prospective therapeutic strategy in chronic myeloid leukemia (CML) cells.